Skip to main content

Table 1 Patient overview

From: 18F-FACBC and 18F-FDG PET/MRI in the evaluation of 3 patients with primary central nervous system lymphoma: a pilot study

Patient number

1

2

3

Age

81

75

64

Sex

Female

Female

Male

Histology

DLBCL

DLBCL

DLBCL

Number of lesions

1

5 (plus 1 pituitary adenoma)

1

Biopsy location

Right basal ganglia

Right nucleus lentifomis

Right basal ganglia

First line treatment

R-MPV × 5 + maintenance Temozolomide

R-MPV × 7 + maintenance Temozolomide

MATRix × 4 + BCNU/Thiotepa ASCT

MRI evaluation after 4 or 5 cycles of treatment

Complete remission

Partial remission

Partial remission

Relapse

yes (13 months after initial diagnosis)

yes (4 months after initial diagnosis)

No (16 months after initial diagnosis)

IELSG score

3

4

4

MSKCC score

2

3

3

ECOG PS

2

2

2

  1. DLBCL Diffuse large B-cell lymphoma, R-MPV rituximab, methotrexate, procarbazine and vincristine, MATRix methotrexate, cytarabine, rituximab, thiotepa, BCNU ASCT carmustine-thiotepa-conditioned autologous stem cell transplantation, IELSG score International Extranodal Lymphoma Study Group score, MSKCC score Memorial Sloan Kettering Cancer Center score, ECOG PS Eastern Cooperative Oncology Group performance scale